Indian-American teen wins top science award worth USD 250,000

March 16, 2017

Washington, Mar 16: An Indian-American teen has won the top award, worth USD 250,000, in the oldest and most prestigious science and math competition in the US, for her research on preventing death of neurons due to brain injuries or neurodegenerative diseases.

American

Indrani Das, a 17-year-old resident of New Jersey, and four other Indian-origin students were among the top ten finalists to be honoured at the annual Regeneron Science Talent Search Awards Gala for their research projects demonstrating exceptional scientific and mathematical ability.

Forty finalists took home more than USD 1.8 million in awards.A contributor to neuron death is astrogliosis, a condition that occurs when cells called astrocytes react to injury by growing, dividing and reducing their uptake of glutamate, which in excess is toxic to neurons.

In a laboratory model, Das showed that exosomes isolated from astrocytes transfected with microRNA-124a both improved astrocyte uptake of glutamate and increased neuron survival.

Arjun Ramani, an 18-year-old student from Indiana won the third place honours worth USD 150,000 for blending the mathematical field of graph theory with computer programming to answer questions about networks.

Typically, these questions require statistical comparisons to hundreds or thousands of random graphs, a process that can take a relatively long time.

He developed an algorithm that greatly accelerated the process by reducing the time required to generate these graphs.

"Congratulations to the Regeneron Science Talent Search 2017 top winners," said George D Yancopoulos, President and Chief Scientific Officer of Regeneron.

"My experience as a Science Talent Search winner led me to embark on a career in science, and I hope it will inspire these exceptional young scientists to become the next generation of innovators that will improve the world and solve some of our most pressing challenges as a society," said Yancopoulos.

Archana Verma, 17, from New York, received a USD 90,000 award for her study of the molecular orbital energy dynamics of dyes, which may someday result in windows that produce solar energy.

Prathik Naidu, 18, from Virginia, received a USD 70,000 award for his creation of a new machine learning software to study 3D interactions of the human genome in cancer.

Vrinda Madan, 17, from Florida, received a USD 50,000 award for her study of 24 potential compounds for the treatment of malaria, in which she found two potential candidates that appear to target the disease-causing organism in a novel way and may warrant further study.

Of more than 1,700 high school seniors who entered the Regeneron Science Talent Search 2017, roughly 300 were named scholars in January.

Of those scholars, 40 students were named finalists and invited to Washington, DC to compete for the top 10 awards.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 4,2020

Madrid, Apr 4: Spain recorded a second successive daily drop in coronavirus-related deaths with 809 fatalities, official figures showed Saturday.

The total number of deaths in Spain now stands at 11,744, second only to Italy. A record 950 people died on Thursday.

The number of new cases also slowed at 7,026, taking the total to 124,736.

Recoveries over the last 24 hours stood at 3,706, taking that total to 34,219.

The Madrid region was the worst affected accounting for 40 percent of the deaths, 4,723, and 29 percent of the cases at 36,249. The northeastern region of Catalonia was in second place with 2,508 deaths.

Prime Minister Pedro Sanchez is due to decide whether to prolong the emergency measures and confinement declared on March 14 for another two weeks in order to get on top of the outbreak.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 24,2020

Paris, Apr 24: The worldwide death toll from the coronavirus pandemic crossed 190,000 on Friday, with nearly two-thirds of the fatalities in Europe, according to an AFP tally compiled from official sources at 0740 GMT.

A total of 190,089 people have died and 2,698,733 been infected since the virus emerged in China in December. The hardest hit continent is Europe, with 116,221 deaths and 1,296,248 cases.

The country with the most deaths is the United States with 49,963, followed by Italy with 25,549, Spain with 22,157, France with 21,856 and Britain 18,738.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.